

PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Kn wn		
				Application Number	09/818,683	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	March 28, 2001	
				First Named Inventor	Ping Feng	
				Art Unit	1631	
				Examiner Name	L. Clow	
heet	1	of	1	Attorney Docket Number	PZ020P1C1	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
4		NISHIZAWA et al., "Identification of a proline-binding motif reglating CD2-triggered T lymphocyte activation," Proc. Natl. Sci. USA., 95:14897-14902, December 1998.				
LAC	B /	FREUND et al, "The GYF domain is a novel structral fold that is involved in lymphoid signaling through proline-rich sequences,' 6:7, pp. 656-660, July 1999.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
TECH CENTER 1600/2900

Date	9/. /
I	1/2/03
	Date Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.